Targeted Therapies in the Gastrointestinal Stromal Tumor (GIST) Market
Targeted therapy has emerged as a transformative treatment approach in the management of Gastrointestinal Stromal Tumors (GISTs). Traditionally, treatment options for GISTs were limited to surgery, which, while effective in localized tumors, often yielded poor results for advanced or metastatic cases. With the advent of targeted therapies, the landscape of GIST treatment has dramatically changed.
The gastrointestinal stromal tumor (GIST) market is estimated to be valued at USD 1.2 Bn in 2024 and is expected to reach USD 2.28 Bn by 2031, growing at a compound annual growth rate (CAGR) of 9.6% from 2024 to 2031.
The most significant breakthrough in the treatment of Gastrointestinal Stromal Tumor (GIST) Market was the development of tyrosine kinase inhibitors (TKIs), which target specific genetic mutations in GIST cells. The vast majority of GISTs are driven by mutations in the KIT or PDGFRA genes, and TKIs like imatinib (Gleevec) have proven to be highly effective in inhibiting the abnormal signaling pathways caused by these mutations. Imatinib is currently the first-line treatment for GIST patients, and its success has paved the way for other tyrosine kinase inhibitors, such as sunitinib (Sutent), regorafenib (Stivarga), and avapritinib (Ayvakit), to be approved for use in patients who are resistant to or intolerant of imatinib.
Get More Insights On- Gastrointestinal Stromal Tumor (GIST) Market
Get This Report in Japanese Language: 消化管間質腫瘍（GIST）市場
Get This Report in Korean Language: 위장관 기질 종양(GIST) 시장
Explore More Related Articles: Rising Cases of Undescended Testicle Around the World
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian